Actelion and Merck form strategic alliance
Message to Shareholders
Highlights
Addresses
Marketing and Sales
Patient Stories
Clinical Development
Clinical Development - Tracleer®
Clinical Development - Veletri™
Clinical Development - Zavesca®
Clinical Development - Clazosentan
Clinical Development - Urotensin II -Receptor Antagonist
Drug Discovery
People
CFO's Letter
Corporate Governance
Report of the group auditors
Consolidated Financial Statements
Notes to the Consolidated Financial Statements
Report of the statutory auditors
Holding Company Statements
Notes to the Financial Statements 2003
Shareholder Information
Overview
Cornerstones
Financials
Financials
THE ACTELION ANNUAL REPORT 2003
CFO's Letter
Corporate Governance
Report of the group auditors
Consolidated Financial Statements
Notes to the Consolidated Financial Statements
Report of the statutory auditors
Holding Company Statements
Notes to the Financial Statements 2003
Shareholder Information
Home
Contact
Legal Disclaimer
Imprint
Actelion.com
